Over 8,000 global entrepreneurs gather in Penang for five days of wellness innovation and mentorship.
HONG KONG, July 11, 2025 /PRNewswire/ -- QNET kicked off...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support
A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) and certain of its officers.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.